Cargando…

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds and mediates endo-lysosomal degradation of low-density lipoprotein receptor (LDLR), limiting plasma clearance of cholesterol-rich LDL particles in liver. Gain-of-function (GOF) point mutations in PCSK9 are associa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarkar, Samantha K., Matyas, Angela, Asikhia, Ikhuosho, Hu, Zhenkun, Golder, Mia, Beehler, Kaitlyn, Kosenko, Tanja, Lagace, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515655/ https://www.ncbi.nlm.nih.gov/pubmed/36187800 http://dx.doi.org/10.3389/fphys.2022.960272

Ejemplares similares

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles
por: Sarkar, Samantha K., et al.
Publicado: (2020)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Studies of the autoinhibitory segment comprising residues 31–60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations
por: Wierød, Lene, et al.
Publicado: (2016)

The anti-Müllerian hormone prodomain is displaced from the hormone/prodomain complex upon bivalent binding to the hormone receptor
por: Cate, Richard L., et al.
Publicado: (2021)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
por: Schulz, Rainer, et al.
Publicado: (2021)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

The Study of the Inhibition of the Recombinant TACE Prodomain to Endotoxemia in Mice
por: Li, Xiaoou, et al.
Publicado: (2009)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis
por: Shaik, Noor Ahmad, et al.
Publicado: (2023)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
por: Rohrbach, Susanne, et al.
Publicado: (2021)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Prodomain of Furin Promotes Phospholipid Transfer Protein Proteasomal Degradation in Hepatocytes
por: Yu, Yang, et al.
Publicado: (2018)

Prodomain–growth factor swapping in the structure of pro-TGF-β1
por: Zhao, Bo, et al.
Publicado: (2018)

The prodomain of caspase-3 regulates its own removal and caspase activation
por: Ponder, Katelyn G., et al.
Publicado: (2019)

Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes
por: Mäkelä, Kari Antero, et al.
Publicado: (2019)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Prodomain Removal Enables Neto to Stabilize Glutamate Receptors at the Drosophila Neuromuscular Junction
por: Kim, Young-Jun, et al.
Publicado: (2015)

Computational analysis of prodomain cysteines in human TGF-β proteins reveals frequent loss of disulfide-dependent regulation in tumors
por: Daly, Samantha M, et al.
Publicado: (2022)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
por: Ying, Qidi, et al.
Publicado: (2021)

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
por: Min, Dong-Kook, et al.
Publicado: (2015)

Alternative mRNA Splicing Generates Two Distinct ADAM12 Prodomain Variants
por: Duhachek-Muggy, Sara, et al.
Publicado: (2013)

The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
por: Jiang, He, et al.
Publicado: (2016)

Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin
por: Malik, Ibrahim, et al.
Publicado: (2017)

Cardiomyopathy related desmocollin-2 prodomain variants affect the intracellular cadherin transport and processing
por: Pohl, Greta Marie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fel1j8b6qpn0kc35c8bds3o1i4